[
  {
    "title": "Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (JAVELIN Renal 101): biomarker analysis of a randomised phase 3 trial",
    "doi": "10.1038/s41591-020-0894-8",
    "journal": "Nature Medicine",
    "year": 2020,
    "full_text_url": "https://www.nature.com/articles/s41591-020-0894-8",
    "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-020-0894-8/MediaObjects/41591_2020_894_MOESM1_ESM.pdf",
    "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150997"
  },
  {
    "title": "Histopathologic and molecular correlates of response to lenvatinib plus pembrolizumab in advanced renal cell carcinoma (CLEAR trial): a biomarker analysis",
    "doi": "10.1016/j.eururo.2023.01.001",
    "journal": "European Urology",
    "year": 2023,
    "full_text_url": "https://www.europeanurology.com/article/S0302-2838(23)00001-2/fulltext",
    "tables_url": "https://www.europeanurology.com/cms/10.1016/j.eururo.2023.01.001/attachment/1e2e7b2d-2e2e-4e2e-8e2e-1e2e7b2d2e2e/mmc1.pdf",
    "data_url": "https://www.europeanurology.com/cms/10.1016/j.eururo.2023.01.001/attachment/1e2e7b2d-2e2e-4e2e-8e2e-1e2e7b2d2e2e/mmc2.pdf"
  },
  {
    "title": "Molecular correlates of response to nivolumab plus cabozantinib in advanced renal cell carcinoma (CheckMate 9ER): a biomarker analysis",
    "doi": "10.1038/s41591-023-02513-2",
    "journal": "Nature Medicine",
    "year": 2023,
    "full_text_url": "https://www.nature.com/articles/s41591-023-02513-2",
    "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-023-02513-2/MediaObjects/41591_2023_2513_MOESM1_ESM.pdf",
    "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223252"
  }
]